Laman UtamaBEAM • BMV
add
Beam Therapeutics Inc
Tutup sebelumnya
$546.25
Julat tahun
$356.51 - $590.00
Permodalan pasaran
2.19B USD
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | 14.27J | -17.01% |
Perbelanjaan pengendalian | 26.52J | 4.35% |
Pendapatan bersih | -96.67J | -0.60% |
Margin untung bersih | -677.47 | -21.22% |
Pendapatan bagi setiap syer | -1.17 | 4.10% |
EBITDA | -101.03J | 1.99% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 925.76J | -8.83% |
Jumlah aset | 1.17B | -9.23% |
Jumlah liabiliti | 380.05J | -25.71% |
Jumlah ekuiti | 791.32J | — |
Syer tertunggak | 79.59J | — |
Harga kepada buku | 54.79 | — |
Pulangan pada aset | -21.89% | — |
Pulangan pada modal | -26.99% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -96.67J | -0.60% |
Tunai daripada operasi | -88.12J | 1.85% |
Tunai daripada pelaburan | 24.70J | 341.43% |
Tunai daripada pembiayaan | 1.26J | -96.57% |
Perubahan bersih dalam tunai | -62.16J | 1.70% |
Aliran tunai bebas | -42.99J | -17.18% |
Perihal
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
CEO
Diasaskan
2017
Tapak web
Pekerja
472
